烏龍製藥 URGN 深 滬
等待開盤 04-01 09:30:00 美东时间
17.98
+0.980
+5.76%
華盛通- 最 高18.525
- 今 開17.36
- 成交量 69.16万股
- 最 低 17.34
- 昨 收 17.00
- 總市值 8.75亿
- 52周最高 30.00
- 市盈率 靜 --
- 換手率 1.42%
- 52周最低 3.42
- 委 比 -12.66%
- 總股本 4868.23万
- 歷史最高 69.568
- 量 比 1.04
- 振 幅 6.97%
- 歷史最低 3.42
- 每 手 1
- 風險率 5.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma announced the publication of long-term results from the Phase 3 ENVISION trial for ZUSDURI, showing a 72.2% probability of remaining event-free at 24 months after achieving complete response (CR). The CR rate at three months was 79.6%, with a median follow-up of 23.7 months. ZUSDURI, approved for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), offers a six-week induction treatment wit...
03-30 12:00
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
A survey of more than 1,100 bladder cancer patients reveals that nearly 80% experience fear of recurrence, rising to over 90% among those under 50. Many patients undergo five or more cystoscopies, with some enduring more than 15 procedures. UroGen Pharma and BCAN highlight the chronic nature of bladder cancer, emphasizing the need for treatment discussions that address long-term quality of life and emotional burden. The report underscores the cum...
03-13 12:00
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. granted 11 new employees inducement restricted stock units (RSUs) to support the commercialization of JELMYTO® and ZUSDUR™ and advance its pipeline. Up to 51,200 shares are issuable upon vesting over three years, contingent on continued employment.
03-06 21:10
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
UroGen Pharma: Q4 Earnings Insights
The Q4 earnings report for UroGen Pharma (NASDAQ:URGN) was released on Monday, ...
03-02 21:02
UroGen Pharma Enters Into Agreement With Funds Managed By Pharmakon Advisors To Revise Terms Of Loan Agreement Entered Into In March 2024
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030$200 million funded at closing to refinance the existing $125 million debt facility
03-02 20:57
Earnings Scheduled For March 2, 2026
Companies Reporting Before The Bell • Zymeworks (NASDAQ:ZYME) is expected to re...
03-02 19:11
UroGen Pharma Earnings Preview
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report...
02-28 02:02
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
UroGen Pharma Ltd. announce the release of their Q4 and full-year 2025 financial results on March 2, 2026, followed by a live webcast and conference call at 10:00 AM ET. The webcast can be accessed on their Investor Relations website, with a replay available for 30 days. UroGen is a biotech company focused on innovative treatments for urothelial and specialty cancers, utilizing their RTGel® technology.
02-23 13:00
